Please use this identifier to cite or link to this item:
https://essuir.sumdu.edu.ua/handle/123456789/87802
Or use following links to share this resource in social networks:
Tweet
Recommend this item
Title | Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study |
Authors |
Felip, E.
Altorki, N.K. Zhou, C. Vallieres, E. Vynnychenko, Ihor Oleksandrovych ![]() Akopov, A. Martinez-Marti, A. Chella, A. Bondarenko, I. Ursol, G. Levchenko, E. Kislov, N. Liersch, R. Belleli, R. McNally, V.A. Bennett, E. Gitlitz, B.J. Wakelee, H. |
ORCID |
http://orcid.org/0000-0002-2339-6509 |
Keywords |
IMpower010 present further analyses |
Type | Conference Papers |
Date of Issue | 2022 |
URI | https://essuir.sumdu.edu.ua/handle/123456789/87802 |
Publisher | Elsevier |
License | Creative Commons Attribution 4.0 International License |
Citation | Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study / E. Felip, N. K. Altorki, C. Zhou et al. // Annals of Oncology. 2022. Volume 33, Issue S2. S 71. |
Abstract |
IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50%
subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses
in PD-L1 TC 50% stage II-IIIA NSCLC pts. |
Appears in Collections: |
Наукові видання (НН МІ) |
Views
![Australia](/flags/au.gif)
1
![Côte d’Ivoire](/flags/ci.gif)
1
![Germany](/flags/de.gif)
1
![Greece](/flags/gr.gif)
1
![Indonesia](/flags/id.gif)
1
![Ireland](/flags/ie.gif)
7151
![South Korea](/flags/kr.gif)
1
![Turkey](/flags/tr.gif)
1
![Ukraine](/flags/ua.gif)
98376
![United Kingdom](/flags/gb.gif)
44204
![United States](/flags/us.gif)
2198931
![Unknown Country](/flags/--.gif)
388735
![Vietnam](/flags/vn.gif)
209
Downloads
![Argentina](/flags/ar.gif)
1
![Denmark](/flags/dk.gif)
1
![France](/flags/fr.gif)
1
![Ireland](/flags/ie.gif)
1
![Israel](/flags/il.gif)
1
![Japan](/flags/jp.gif)
859
![Malaysia](/flags/my.gif)
4330
![Netherlands](/flags/nl.gif)
194581
![Poland](/flags/pl.gif)
1
![Singapore](/flags/sg.gif)
1
![Ukraine](/flags/ua.gif)
2198930
![United Kingdom](/flags/gb.gif)
582887
![United States](/flags/us.gif)
2198929
![Unknown Country](/flags/--.gif)
388736
![Vietnam](/flags/vn.gif)
1
Files
File | Size | Format | Downloads |
---|---|---|---|
Felip_et_al_Atezolizumab_2022.pdf | 156,83 kB | Adobe PDF | 5569260 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.